15 October2026: MacroGenics dosed the first patient in the phase 1 trial of MGC030 for advanced Solid tumors
MacroGenics announced that the first patient has been dosed in the phase 1 clinical trial of MGC030, its investigational ADC targeting an undisclosed antigen, in patients with advanced solid tumors. The milestone advances the program into first-in-human clinical evaluation
The phase 1 study is an open-label trial incorporating dose escalation, dose optimization and cohort expansion to evaluate safety, tolerability, pharmacokinetics, immunogenicity and preliminary antitumor activity. It will enroll patients with relapsed or refractory, unresectable, locally advanced or metastatic urothelial, colorectal, gastric/gastroesophageal junction, esophageal and pancreatic cancers
The program addresses the need for new targeted treatments in advanced solid tumors, particularly in patients whose disease has progressed following standard therapies. MacroGenics reports encouraging preclinical antitumor activity across multiple in vivo models
MGC030 is a topoisomerase I inhibitor-based ADC incorporating Synaffix’s proprietary conjugation technology and SYNtecan E linker-payload platform. It uses a cleavable, exatecan-based cytotoxic payload with a drug-to-antibody ratio of 4
Strategically, MGC030 becomes MacroGenics’ third ADC in active clinical development, complementing its B7-H3-directed MGC026 and ADAM9-directed MGC028 programs. Its entry into clinical testing expands the company’s Topo-I ADC pipeline and creates an opportunity to assess a new target across several solid tumors